Table 2 Comparison between genes uncovered in this study and other cancers. Literature analysis of the genes not previously reported as deregulated in CRC, but found deregulated in other cancer types. Different expression data information was listed for each gene: i) from our study performed by PCR array technology in CRC (n = 95) as compared to NT (n = 19); ii) from literature data by focusing on expression analysis obtained in other cancers (RNA or protein level) and iii) from other literature data obtained from genetic association, epigenetic and functional studies in other cancers. Bold lines highlight newly deregulated genes in CRC and not associated to other cancers
From: A transcriptome-based protein network that identifies new therapeutic targets in colorectal cancer
Gene Symbol | PCR Array Data (CRC vs. NT) | Bibliography Data | |||||
|---|---|---|---|---|---|---|---|
Fold-change | q-value | Pathway | Type of Cancer | Expression Change (vs. NT) | Ref. | Other data | |
CEL | 15.08 | < 0.001 | Chol. Met. | Pancreas | ↓ (RNA) | [25] | / |
Nasopharynx | ↑ (RNA) | [24] | / | ||||
PCSK9 | 6.28 | < 0.001 | Chol. Met. | Lung | ↓ (RNA) | [23] | PCSK9 deficiency reduces liver metastasis [64]. |
INSIG1 | 3.69 | < 0.001 | Chol. Met. | Breast | ↑ (protein) | [65] | / |
DHCR7 | 3.56 | < 0.001 | Chol. Met. | / | / | / | / |
CYP39A1 | 3.35 | < 0.001 | Chol. Met. | Cholangiosarcoma | ↓ (protein) | [66] | / |
APOL1 | 2.97 | < 0.001 | Chol. Met. | / | / | / | / |
CYP51A1 | 2.95 | < 0.001 | Chol. Met. | / | / | / | / |
HMGCS1 | 2.79 | < 0.001 | Chol. Met. | / | / | / | Non-synonymous mutation associated to hepatocellular carcinoma [67]. |
NSDHL | 2.61 | < 0.001 | Chol. Met. | / | / | / | / |
CYP2B6 | 2.61 | < 0.05 | Drug Met. | Breast | ↑ (RNA) | [68] | / |
Hepatocellular | ↑ (RNA) | [69] | |||||
DHCR24 | 2.44 | < 0.01 | Chol. Met. | Adrenals | ↓ (RNA) | [70] | / |
Prostate | ↑ low risk and ↓ advanced (protein) | [71] | |||||
FDPS | 2.40 | < 0.001 | Chol. Met. | Prostate | ↑ (protein, RNA) | / | |
SRD5A1 | 2.37 | < 0.001 | Drug Met. | Non-small cell lung cancer | ↑ (RNA) | [74] | / |
Prostate | ↑ (RNA, protein) | [75] | Associated with biological aggressiveness in prostate cancer [76]. | ||||
Breast | ↑ (RNA) | [77] | / | ||||
IDI1 | 2.37 | < 0.001 | Chol. Met. | / | / | / | Altered expression in response to paclitaxel treatment in ovarian carcinoma (nude mice xenografts) [78]. |
EPDR1 | 2.25 | < 0.01 | Cancer | / | / | / | / |
CNBP | 2.09 | < 0.001 | Chol. Met. | / | / | / | / |
FDFT1 | 2.01 | < 0.01 | Chol. Met. | Gastric | ↑ (RNA, protein) | [79] | The A allele of rs2645429 (promoter) was significantly associated with prostate cancer risk in a Japanese familial population (~increase promoter activity) [80]. |
Prostate | ↑ (RNA) | [80] | |||||
TM7SF2 | 1.96 | < 0.001 | Chol. Met. | Adrenocortical tumors | ↓ (RNA) | [81] | / |
Follicular thyroid carcinoma | ↑ aggressive vs. non-aggressive (RNA) | [82] | |||||
RIPK2 | 1.95 | < 0.001 | Apoptosis | Breast | ↑ (RNA) | [83] | KO of RIPK2 in murine model of bladder Cancer induces large tumors and higher incidence of metastases [84]. |
Oral squamous cell carcinoma | ↓ (protein) | [85] | |||||
SREBF1 | 1.93 | < 0.001 | Chol. Met. | Hepatocellular | ↑ (RNA, protein) | [86] | / |
SORL1 | 1.90 | < 0.01 | Chol. Met. | Astrocytoma | ↑ (RNA) | [87] | / |
GSR | 1.82 | < 0.05 | Drug Met. | / | / | / | / |
MVK | 1.72 | < 0.001 | Chol. Met. | / | / | / | / |
GSTM5 | −3.92 | < 0.001 | Drug Met. | Barett’s esophagus | ↓ (RNA) | [27] | Associated to DNA hypermethylation in Barett’s adenocarcinoma [27], in human salivary gland adenoid cystic carcinoma [88], in myelodysplasic syndrome [89], in glioblastoma [26]. |
Glioblastoma | [26] | ||||||
COLEC12 | −3.32 | < 0.001 | Chol. Met. | Anaplastic thyroid carcinoma | ↓ (RNA) | [90] | / |
GSTM2 | −3.10 | < 0.001 | Drug Met. | Barett’s esophagus | ↓ (RNA) | [27] | |
Oral squamous cell carcinoma | [91] | ||||||
GSTM3 | −2.49 | < 0.001 | Drug Met. | Barett’s esophagus | ↓ (RNA) | [27] | Associated to DNA hypermethylation in Barett’s adenocarcinoma [27]. |
Lung | [92] | ||||||
CD27 | −2.30 | < 0.001 | Apoptosis | Bladder | ↓ (RNA) | [93] | / |
B Cell Lymphoma | ↑ (protein) | [94] | |||||
CLL | ↑ (RNA) | [95] | |||||
TEK | −2.30 | < 0.001 | Cancer | Non-small cell lung cancer | ↓ (RNA) | [96] | / |
Angiosarcoma | ↑ (RNA) | [97] | |||||
AML and CML | [98] | ||||||
Thyroid | ↑ (RNA, protein) | [99] | |||||
Breast | ↑ (protein) | [100] | |||||
RHOU | −1.78 | < 0.001 | Wnt | Prostate | ↓ (RNA) | [101] | / |
WNT2B | −2.19 | < 0.001 | Wnt | Pancreas | ↑ (protein) | [102] | / |
Stomach | ↑ (RNA) | [103] | |||||
Basal carcinoma (skin) | ↑ (RNA) | [104] | |||||
ITGA4 | −2.13 | < 0.001 | Cancer | CLL | ↑ (RNA, protein) | [105] | / |
ITGB3 | −2.11 | < 0.001 | Cancer | Liver | ↓ (RNA, protein) | [106] | / |
Ovary | ↑ (RNA, protein) | [107] | |||||
CD40LG | −2.09 | < 0.001 | Apoptosis | Inflammatory breast cancer | ↑ (RNA) | [108] | / |
CELA3A | −2.04 | < 0.001 | Chol. Met. | Mucinous pancreatic cyst | ↑ (protein) vs non mucinous | [109] | / |
PRKAA2 | −1.96 | < 0.001 | Chol. Met. | Ovary | ↑ (RNA) | [110] | / |
CYP2C19 | −1.94 | < 0.001 | Drug Met. | Breast | ↓ (protein) | [68] | / |
Liver | ↑ (RNA) | [111] | |||||
CYP11A1 | −1.85 | < 0.001 | Chol. Met. | Prostate | ↓ (RNA) | [112] | Associated to DNA hypermethylation in prostate cancer [112]. |
Endometrium | [113] | ||||||
WNT5B | −1.83 | < 0.001 | Wnt | CLL | ↑ (RNA) | / | |
Uterine leiomyoma | [116] | ||||||
FRZB | −1.73 | < 0.01 | Wnt | Liver | ↓ (RNA) | [117] | Associated to DNA hypermethylation in hepatocellular carcinoma [117], medulloblastoma [118] and bladder cancer [119]. |
Melanoma | [120] | ||||||
Medulloblastoma | [118] | ||||||
Bladder | [119] | ||||||
Gastric | [121] | ||||||
Breast | [122] | ||||||
WNT9A | −1.68 | < 0.001 | Wnt | CLL | ↑ (RNA) | / | |
STAB2 | −1.68 | < 0.001 | Chol. Met. | Liver | ↓ (protein) | [123] | / |